Meta-analysis
Atrial Fibrillation Incidence Associated With Exposure to Anticancer Drugs Used as Monotherapy in Clinical Trials
- Systematic review and meta-analysis of phase 2 and 3 clinical trials
- random-effects
Authors' conclusion
AF reporting is not a rare event associated with anticancer drugs in clinical trials.
Study context
- Population
- Cancer patients in phase 2 and 3 trials of 19 anticancer drugs used as monotherapy (ClinicalTrials.gov, up to September 18, 2020)
- Participants
- 26,604 patients · 191 trials
- Comparison
- Anticancer drug monotherapy vs placebo
- Outcome
- Annualized incidence rate of atrial fibrillation (AF) reporting
Pooled result
As reported in the abstract
Annualized incidence rate of AF reporting (per 100 person-years)
- Range across the 15 drugs with calculable rates
- 0.26 to 4.92 per 100 person-years
Original publication
Atrial Fibrillation Incidence Associated With Exposure to Anticancer Drugs Used as Monotherapy in Clinical Trials. JACC CardioOncol. Published 28 March 2023. doi:10.1016/j.jaccao.2022.11.019
Summarised from the published abstract; every number is checked against it